About Event
Welcome to the 5th RAS-Targeted Drug Development Summit!
As the only industry-dedicated, end-to-end meeting focused on the next generation of drugs targeting RAS cancers, the 5th RAS Targeted Drug Development Summit brought together 150+ key opinion leaders to accelerate RAS-targeted drug discovery, advance pre-clinical drugs to clinic, and optimize translational and clinical development.
Industry leaders such as Mirati Therapeutics, Revolution Medicines, Amgen, Novartis, Roche and Loxo Oncology@Lilly delivered technical, data-led clinical updates and workshops on the translational and clinical development track. On the other hand, promising candidates such as BridgeBio, Biotheryx, Pfizer, and Genentech delivered on the early discovery and pre-clinical track.
This was an opportunity to network with the key stakeholders and decision-makers of the RAS industry including CXOs, VPs, Senior Directors and Global Leads of Oncology, Translational and Clinical Sciences, Chemistry and Biology as well as key academics and oncologists such as Frank McCormick, Channing Der, Chiara Ambrogio, Andrew Aguirre, Mark Awad and Poulikos Poulikakos.
What You Missed:
Adagrasin”ing” the Opportunity: Latest Updates from the G12C Inhibitor for Combatting NSCLC & Other Cancers with Debra Ryan from Mirati Therapeutics
The Story of Sotorasib: Learnings from the Journey of the First Approved RAS-Targeted Drug with Emily Chan from Amgen
Program Updates from LY3537982, A Highly Selective & Potent KRAS G12C Inhibitor with Arjun Balar from Loxo Oncology@Lily
RMC-0708: Showcasing A First-In-Class Mutant-Selective RAS(ON) Inhibitor to Combat KRASQ61H Cancers with Kevin Yang from Revolution Medicines
From Approval to Accessible: Lessons Learned About the Promotion, Adoption & Reimbursement of RAS-Targeted Therapies with Ashita Nayak from Amgen and Allison Zavitz from Roche
For more details about the program, speaker faculty or pricing and discounts, download the brochure.